Agenus to Report Second Quarter 2016 Financial Results on July 28, 2016; Conference Call to Follow
July 21 2016 - 8:50AM
Business Wire
Agenus Inc. (NASDAQ: AGEN) will release its second quarter 2016
financial results before the market opens on Thursday, July 28,
2016. Agenus executives will host a conference call at 11 a.m.
Eastern Time the same day.
To access the live call, dial 1-888-799-5016 (U.S.) or
1-704-908-0465 (International) and refer to conference ID number
50188771. The call will also be webcast and will be accessible from
the company’s website at www.agenusbio.com/webcast/. A replay of
the webcast will be available on the company’s website for
approximately 60 days after the call.
About Agenus
Agenus is an immuno-oncology company focused on the discovery
and development of revolutionary new treatments that engage the
body’s immune system to benefit patients suffering from cancer. By
combining multiple powerful platforms, Agenus has established a
highly integrated approach for the discovery, development and
manufacture of monoclonal antibodies that modulate targets of
interest. In addition, the Company’s cancer vaccine program
includes three proprietary platforms focused on individualized and
off-the-shelf vaccines uniquely designed for each patient. Agenus’
broad portfolio of novel checkpoint and other immuno-modulatory
monoclonal antibodies, vaccines and adjuvants work in combination
to provide the opportunity to create best-in-class therapeutic
regimens. The Company has formed collaborations with Merck and
Incyte to discover and develop multiple checkpoint antibodies. For
more information, please visit www.agenusbio.com; information
that may be important to investors will be routinely posted on our
website.
Forward-Looking Statement
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding the Company’s
anticipated timing for releasing its second quarter 2016 financial
results. These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include, among others, the factors
described under the Risk Factors section of Agenus’ Form 10-Q filed
with the Securities and Exchange Commission on May 9, 2016. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160721005204/en/
Agenus:Agenus Inc.Michelle Linn,
781-674-4541michelle.linn@agenusbio.comorMedia:BMC
CommunicationsBrad Miles,
646-513-3125bmiles@bmccommunications.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024